CircDCAF8 promotes the progression of hepatocellular carcinoma through miR-217/NAP1L1 Axis, and induces angiogenesis and regorafenib resistance via exosome-mediated transfer.

Authors: Gong, Jiahao^1,2 (AUTHOR), Han, Guoyong^1,2 (AUTHOR), Chen, Zhiqiang^1,2 (AUTHOR), Zhang, Yinqi^1,2 (AUTHOR), Xu, Bin³ (AUTHOR), Xu, Chao^1,2 (AUTHOR), Gao, Wen⁴ (AUTHOR) gaowen@jsph.org.cn, Wu, Jindao^1,2 (AUTHOR) wujindao@njmu.edu.cn

Source: Journal of Translational Medicine. 5/30/2024, Vol. 22, p1-20. 20p.

Subject Terms: *REGORAFENIB, *NEOVASCULARIZATION, *CIRCULAR RNA, *RNA-binding proteins, *POLYMERASE chain reaction, *HEPATOCELLULAR carcinoma

Exploring Regorafenib Responsiveness and Uncovering Molecular Mechanisms in Recurrent Glioblastoma Tumors through Longitudinal In Vitro Sampling.

Authors: Morelli, Mariangela¹ (AUTHOR) f.lessi@fpscience.it, Lessi, Francesca¹ (AUTHOR) s.franceschi@fpscience.it, Franceschi, Sara¹ (AUTHOR) m.giacomarra@fpscience.it, Ferri, Gianmarco¹ (AUTHOR) c.mazzanti@fpscience.it, Giacomarra, Manuel¹ (AUTHOR), Menicagli, Michele¹ (AUTHOR), Gambacciani, Carlo² (AUTHOR) orazio.santonocito@uslnordovest.toscana.it, Pieri, Francesco² (AUTHOR), Pasqualetti, Francesco³ (AUTHOR), Montemurro, Nicola⁴ (AUTHOR) nicola.montemurro@unipi.it, Aretini, Paolo¹ (AUTHOR), Santonocito, Orazio Santo² (AUTHOR), Di Stefano, Anna Luisa² (AUTHOR), Mazzanti, Chiara Maria¹ (AUTHOR)

Source: Cells (2073-4409). Mar2024, Vol. 13 Issue 6, p487. 19p.

Subject Terms: *GLIOBLASTOMA multiforme, *REGORAFENIB, *BRAIN tumors, *TUMORS, *INDIVIDUALIZED medicine

Advanced gastrointestinal stromal tumor: reliable classification of imatinib plasma trough concentration via machine learning.

Authors: Ran, Pan¹ (AUTHOR), Tan, Tao¹ (AUTHOR), Li, Jinjin¹ (AUTHOR), Yang, Hao² (AUTHOR), Li, Juan³ (AUTHOR) zpfirst@sina.com, Zhang, Jun¹ (AUTHOR) zjun2323@sina.cn

Source: BMC Cancer. 2/24/2024, Vol. 24 Issue 1, p1-14. 14p.

Subject Terms: *REGORAFENIB, *GASTROINTESTINAL stromal tumors, *TUMOR classification, *BLOOD cell count, *MACHINE learning, *IMATINIB, *ERYTHROCYTES

Geographic Terms: CHINA

Design and evaluation of sustained-release lipid-PLGA hybrid nanoparticles for enhanced anticancer efficacy of 5-fluorouracil.

Authors: Khan, Safiullah^1,2, safiullahkhan856@gmail.com, Madni, Asadullah¹, Aamir, Muhammad Naeem¹, Khan, Shahzeb³, Ahmad, Fiaz-ud-Din⁴, Basit, Abdul⁵, Jan, Nasrullah⁶, Shah, Hassan⁷, Shafiq, Afifa¹, Anwar, Maryam⁸

Source: Particulate Science & Technology; 2024, Vol. 42 Issue 2, p269-287, 19p

Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.

Authors: Taşçı, Elif Şenocak¹ (AUTHOR) esenocak@gmail.com, Oyan, Başak² (AUTHOR), Sönmez, Özlem² (AUTHOR), Mutlu, Arda Ulaş² (AUTHOR), Atcı, Muhammed Mustafa³ (AUTHOR), Sakin, Abdullah⁴ (AUTHOR), Öner, İrem⁵ (AUTHOR), Çınkır, Havva Yeşil⁶ (AUTHOR), Eryılmaz, Melek Karakurt⁷ (AUTHOR), Çağlayan, Dilek⁷ (AUTHOR), Balçık, Onur Yazdan⁸ (AUTHOR), Paksoy, Nail⁹ (AUTHOR), Karabulut, Senem¹⁰ (AUTHOR), Salim, Derya Kıvrak¹¹ (AUTHOR), Bilir, Cemil¹² (AUTHOR), Özen, Miraç¹³ (AUTHOR), Özçelik, Melike¹⁴ (AUTHOR), Arıcan, Ali² (AUTHOR), Akagündüz, Baran¹⁵ (AUTHOR), İnal, Ali¹⁶ (AUTHOR)

Source: BMC Cancer. 1/22/2024, Vol. 24 Issue 1, p1-10. 10p.

Subject Terms: *COLORECTAL cancer, *REGORAFENIB, *METASTASIS, *PROGRESSION-free survival, *CANCER chemotherapy

Baseline Albumin-Bilirubin grade as a predictor of response and outcome of regorafenib therapy in patients with hepatocellular carcinoma: a systematic review and meta-analysis.

Authors: Xu, Huilin¹ (AUTHOR) xhlcdd@163.com, Cao, Dedong² (AUTHOR), Zhou, Dingjie² (AUTHOR), Zhao, Nan² (AUTHOR), Tang, Xixian² (AUTHOR), Shelat, Vishalkumar G.³ (AUTHOR), Samant, Hrishikesh⁴ (AUTHOR), Satapathy, Sanjaya K.⁵ (AUTHOR), Tustumi, Francisco⁶ (AUTHOR), Aprile, Giuseppe⁷ (AUTHOR), He, Anbing¹ (AUTHOR), Xu, Ximing² (AUTHOR), Ge, Wei⁸ (AUTHOR)

Source: BMC Cancer. 10/19/2023, Vol. 23 Issue 1, p1-10. 10p.

Subject Terms: *HEPATOCELLULAR carcinoma, *REGORAFENIB, *PROGRESSION-free survival, *SURVIVAL rate, *PROGNOSIS

Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study.

Authors: Xu, Yongkang (AUTHOR), Fu, Shumin (AUTHOR), Liu, Kan (AUTHOR), Mao, Ye (AUTHOR), Wu, Jianbing (AUTHOR)

Source: Therapeutics & Clinical Risk Management. Oct2023, Vol. 19, p853-863. 11p.

Subject Terms: *SORAFENIB, *REGORAFENIB, *PROGRAMMED cell death 1 receptors, *PROGNOSIS, *SURVIVAL rate, *TREATMENT failure, *SURVIVAL analysis (Biometry)

REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial.

Authors: Martin-Broto, Javier^1,2,3 (AUTHOR) jmartin@atbsarc.org, Valverde, Claudia⁴ (AUTHOR), Hindi, Nadia^1,2,3 (AUTHOR), Vincenzi, Bruno⁵ (AUTHOR), Martinez-Trufero, Javier⁶ (AUTHOR), Grignani, Giovanni⁷ (AUTHOR), Italiano, Antoine⁸ (AUTHOR), Lavernia, Javier⁹ (AUTHOR), Vallejo, Ana¹⁰ (AUTHOR), Tos, Paolo Dei¹¹ (AUTHOR), Le Loarer, Francois¹² (AUTHOR), Gonzalez-Campora, Ricardo¹³ (AUTHOR), Ramos, Rafael¹⁴ (AUTHOR), Hernández-Jover, Diana¹⁵ (AUTHOR), Gutierrez, Antonio¹⁶ (AUTHOR), Serrano, Cesar⁴ (AUTHOR), Monteagudo, Maria¹⁷ (AUTHOR), Letón, Rocio¹⁷ (AUTHOR), Robledo, Mercedes^17,18 (AUTHOR), Moura, David S.¹ (AUTHOR)

Source: Molecular Cancer. 8/9/2023, Vol. 22 Issue 1, p1-8. 8p.

Subject Terms: *GASTROINTESTINAL stromal tumors, *REGORAFENIB, *C-kit protein, *COVID-19 pandemic, *PROTEIN-tyrosine kinase inhibitors, *SARCOMA, *DASATINIB

Early low blood MALT1 expression levels forecast better efficacy of PD-1 inhibitor-based treatment in patients with metastatic colorectal cancer.

Authors: CHUANMING LI¹, FAN YU¹, WANLI XU² xinci7160204@163.com

Source: Oncology Letters. Aug2023, Vol. 26 Issue 2, p1-11. 11p.

Subject Terms: *MUCOSA-associated lymphoid tissue lymphoma, *REGORAFENIB, *COLORECTAL cancer, *REVERSE transcriptase polymerase chain reaction, *PROGRAMMED cell death 1 receptors, *CETUXIMAB, *METASTASIS

Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma.

Authors: Li, Jinpeng (AUTHOR), Jia, Yuntao (AUTHOR), Shao, Changdong (AUTHOR), Li, Yuanming (AUTHOR), Song, Jinlong (AUTHOR)

Source: Therapeutics & Clinical Risk Management. Apr2023, Vol. 19, p329-339. 11p.

Subject Terms: *IMMUNE checkpoint inhibitors, *REGORAFENIB, *ADVERSE health care events, *PROGRESSION-free survival, *PROGNOSIS

Combining Three Tyrosine Kinase Inhibitors: Drug Monitoring Is the Key.

Authors: Thomas, Quentin Dominique^1,2 (AUTHOR) quentin.thomas@icm.unicancer.fr, Firmin, Nelly^1,2 (AUTHOR), Mbatchi, Litaty^2,3 (AUTHOR), Evrard, Alexandre^2,3 (AUTHOR), Quantin, Xavier^1,2 (AUTHOR), Leenhardt, Fanny^1,2,3 (AUTHOR)

Source: International Journal of Molecular Sciences. Mar2023, Vol. 24 Issue 6, p5518. 7p.

Subject Terms: *PROTEIN-tyrosine kinase inhibitors, *REGORAFENIB, *DRUG monitoring, *EPIDERMAL growth factor receptors, *NON-small-cell lung carcinoma, *DRUG utilization

INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG).

Authors: Lam, Lyn Ley¹ (AUTHOR) integrateii.study@sydney.edu.au, Pavlakis, Nick² (AUTHOR), Shitara, Kohei³ (AUTHOR), Sjoquist, Katrin M.¹ (AUTHOR), Martin, Andrew J.¹ (AUTHOR), Yip, Sonia¹ (AUTHOR), Kang, Yoon-Koo⁴ (AUTHOR), Bang, Yung-Jue⁵ (AUTHOR), Chen, Li-Tzong⁶ (AUTHOR), Moehler, Markus⁷ (AUTHOR), Bekaii-Saab, Tanios⁸ (AUTHOR), Alcindor, Thierry⁹ (AUTHOR), O'Callaghan, Christopher J.¹⁰ (AUTHOR), Tebbutt, Niall C.¹⁰ (AUTHOR), Hague, Wendy¹ (AUTHOR), Chan, Howard¹¹ (AUTHOR), Rha, Sun Young¹² (AUTHOR), Lee, Keun-Wook^5,13 (AUTHOR), Gebski, Val¹ (AUTHOR), Jaworski, Anthony¹ (AUTHOR)

Source: BMC Cancer. 2/22/2023, Vol. 23 Issue 1, p1-12. 12p.

Subject Terms: *CLINICAL trials, *REGORAFENIB, *PROGRESSION-free survival, *VASCULAR endothelial growth factor antagonists, *PROTEIN-tyrosine kinase inhibitors

Phase II dose titration study of regorafenib in progressive unresectable metastatic colorectal cancer.

Authors: Kato, Takeshi¹ (AUTHOR), Kudo, Toshihiro² (AUTHOR) tkudo@mc.pref.osaka.jp, Kagawa, Yoshinori³ (AUTHOR), Murata, Kohei³ (AUTHOR), Ota, Hirofumi⁴ (AUTHOR), Noura, Shingo⁵ (AUTHOR), Hasegawa, Junichi⁵ (AUTHOR), Tamagawa, Hiroshi⁶ (AUTHOR), Ohta, Katsuya⁷ (AUTHOR), Ikenaga, Masakazu⁷ (AUTHOR), Miyazaki, Susumu⁸ (AUTHOR), Komori, Takamichi⁸ (AUTHOR), Uemura, Mamoru⁹ (AUTHOR), Nishimura, Junichi⁹ (AUTHOR), Hata, Taishi⁹ (AUTHOR), Matsuda, Chu⁹ (AUTHOR), Satoh, Taroh² (AUTHOR), Mizushima, Tsunekazu⁹ (AUTHOR), Ohno, Yuko¹⁰ (AUTHOR), Yamamoto, Hirofumi⁹ (AUTHOR)

Source: Scientific Reports. 2/9/2023, Vol. 13 Issue 1, p1-8. 8p.

Subject Terms: *REGORAFENIB, *COLORECTAL cancer, *CLINICAL trials, *METASTASIS, *FOOT, *VOLUMETRIC analysis, *PROGRESSION-free survival

PROPERTY: study protocol for a randomized, double-blind, multicenter placebo-controlled trial assessing neurotoxicity in patients with metastatic gastrointestinal cancer taking PHYCOCARE® during oxaliplatin-based chemotherapy.

Authors: Le Gouill-Jaijarat, Christele¹ (AUTHOR), Péréon, Yann² (AUTHOR), Leroy, Maxime³ (AUTHOR), Lépine, Olivier⁴ (AUTHOR), Loloum, Aymeric⁴ (AUTHOR), Peluchon, Claire^1,5 (AUTHOR), Volteau, Christelle³ (AUTHOR), Martineau, Anne-Sophie³ (AUTHOR), Korner, Simon³ (AUTHOR), Perrault, Caroline³ (AUTHOR), Benmaziane, Asmahane⁶ (AUTHOR), Girot, Paul⁷ (AUTHOR), Petorin, Caroline⁸ (AUTHOR), Perret, Clément⁹ (AUTHOR), Ligeza-Poisson, Catherine¹⁰ (AUTHOR), Mayeur, Didier¹¹ (AUTHOR), Flet, Laurent¹² (AUTHOR), Chiffoleau, Anne³ (AUTHOR), Poinas, Alexandra⁵ (AUTHOR) Alexandra.poinas@chu-nantes.fr, Bennouna, Jaafar⁶ (AUTHOR)

Source: Trials. 1/20/2023, Vol. 24 Issue 1, p1-13. 13p. 2 Diagrams, 4 Charts.

Subject Terms: *MEDICAL personnel, *REGORAFENIB, *GASTROINTESTINAL cancer, *CETUXIMAB, *METASTASIS, *NEUROTOXICOLOGY, *CANCER chemotherapy

The OCT2/MATE1 Interaction Between Trifluridine, Metformin and Cimetidine: A Crossover Pharmacokinetic Study.

Authors: Guchelaar, Niels A. D.¹ (AUTHOR) n.guchelaar@erasmusmc.nl, Buck, Stefan A. J.¹ (AUTHOR), van Doorn, Leni¹ (AUTHOR), Hussaarts, Koen G. A. M.¹ (AUTHOR), Sandberg, Yorick² (AUTHOR), van der Padt-Pruijsten, Annemieke^1,2 (AUTHOR), van Alphen, Robbert J.³ (AUTHOR), Poppe-Manenschijn, Laura⁴ (AUTHOR), Vleut, Isolde⁵ (AUTHOR), de Bruijn, Peter¹ (AUTHOR), van Leeuwen, Roelof W. F.⁵ (AUTHOR), Mostert, Bianca¹ (AUTHOR), Eskens, Ferry A. L. M.¹ (AUTHOR), Oomen-de Hoop, Esther¹ (AUTHOR), Koolen, Stijn L. W.^1,5 (AUTHOR), Mathijssen, Ron H. J.¹ (AUTHOR)

Source: Clinical Pharmacokinetics. Jul2024, Vol. 63 Issue 7, p1037-1044. 8p.

Subject Terms: *IRINOTECAN, *REGORAFENIB, *METFORMIN, *ORGANIC cation transporters, *CIMETIDINE, *PHARMACOKINETICS, *BONFERRONI correction, *DRUG interactions

Imatinib use for gastrointestinal stromal tumors among older patients in Japan and Taiwan.

Authors: Ichinose, Yuichi¹ (AUTHOR) yuichino@ncc.go.jp, Yang, Yi-Hsin² (AUTHOR) yhyang@nhri.edu.tw, Tsai, Hui-Jen² (AUTHOR), Huang, Ru-Yu² (AUTHOR), Higashi, Takahiro^1,3 (AUTHOR), Nishida, Toshirou^4,5 (AUTHOR), Chen, Li-Tzong^2,6,7 (AUTHOR)

Source: Scientific Reports. 12/28/2022, Vol. 12 Issue 1, p1-10. 10p.

Subject Terms: *REGORAFENIB, *OLDER patients, *GASTROINTESTINAL stromal tumors, *NILOTINIB, *SORAFENIB, *IMATINIB, *PROTEIN-tyrosine kinase inhibitors

Geographic Terms: TAIWAN, JAPAN

Regorafenib and trifluridine/tipiracil in real clinical practice.

Authors: García-Beloso, Nerea¹ (AUTHOR), Romero-Ventosa, Elena¹ (AUTHOR), Gayoso-Rey, Mónica¹ (AUTHOR), López-López, Aida¹ (AUTHOR), Robles-Torres, David¹ (AUTHOR), de Castro, Noemí¹ (AUTHOR), Piñeiro-Corrales, Guadalupe¹ (AUTHOR)

Source: Journal of Cancer Research & Therapeutics. 2022 Suppl 2, Vol. 18, p367-373. 7p.

Subject Terms: *REGORAFENIB, *PROGRESSION-free survival, *OVERALL survival, *COLORECTAL cancer, *ORAL medication

Geographic Terms: SPAIN

Modification of MRI pattern of high‐grade glioma pseudoprogression in regorafenib therapy.

Authors: Mansour, Mariam¹ (AUTHOR), Vitale, Valerio¹ (AUTHOR) valerio.vitale@aulss8.veneto.it, Lombardi, Giuseppe² (AUTHOR), Riva, Giulio³ (AUTHOR), Pancheri, Francesca⁴ (AUTHOR), Zanusso, Mariano⁵ (AUTHOR)

Source: Journal of Medical Imaging & Radiation Oncology. Apr2022, Vol. 66 Issue 3, p414-418. 5p.

Subject Terms: *DIFFUSION magnetic resonance imaging, *REGORAFENIB, *MAGNETIC resonance imaging, *GLIOMAS, *PERFUSION imaging, *BLOOD volume

Regorafenib with immunotherapy versus regorafenib alone as second‐line treatment for hepatocellular carcinoma: A multicenter real‐world study.

Authors: Qiao, Liang^1,2 (AUTHOR), He, Wei^1,2 (AUTHOR), Wang, Guoying^3,4 (AUTHOR), Chen, Huanwei⁵ (AUTHOR), Huang, Fuxi⁶ (AUTHOR), Zhang, Bo⁷ (AUTHOR), Qiu, Yuxiong^1,2 (AUTHOR), Liu, Shaoru^1,2 (AUTHOR), Huang, Zhenkun^1,2 (AUTHOR), Yuan, Yichuan^1,2 (AUTHOR), Qiu, Jiliang^1,2 (AUTHOR), Yuan, Yunfei^1,2 (AUTHOR) yuanyf@mail.sysu.edu.cn, Li, Binkui^1,2 (AUTHOR) libk@sysucc.org.cn

Source: Cancer Medicine. May2024, Vol. 13 Issue 9, p1-13. 13p.

Subject Terms: *REGORAFENIB, *IMMUNE checkpoint inhibitors, *PROPENSITY score matching, *ADVERSE health care events, *HEALTH facilities, *HEPATOCELLULAR carcinoma

Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration.

Authors: Piscitelli, Joseph¹ (AUTHOR), Reddy, Micaela B.² (AUTHOR), Wollenberg, Lance² (AUTHOR), Del Frari, Laurence³ (AUTHOR), Gong, Jason⁴ (AUTHOR), Wood, Linda⁵ (AUTHOR), Zhang, Yizhong⁵ (AUTHOR), Matschke, Kyle⁶ (AUTHOR), Williams, Jason H.¹ (AUTHOR) jason.williams@pfizer.com

Source: Clinical Pharmacokinetics. Apr2024, Vol. 63 Issue 4, p483-496. 14p.

Subject Terms: *REGORAFENIB, *ROSUVASTATIN, *RECEIVER operating characteristic curves, *BUPROPION, *STATINS (Cardiovascular agents), *DRUG interactions